Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel vitronectin antagonist and use in osteoporosis disclosed by Aventis and Genentech

June 7, 2002

Esperion claims ether compounds for use in lipoprotein disorders, etc.

June 7, 2002

Neulasta recommended for approval in E.U. for reduction of chemotherapy-induced neutropenia

June 6, 2002

Arrest of type 1 diabetes achieved with short-term use of antibody

June 6, 2002

CPMP recommends approval of ARANESP for anemia in cancer patients

June 5, 2002

Dyax and Genzyme restructure DX-88 collaboration

June 5, 2002

Cellegy submits NDA for Tostrex in male hypogonadism

June 5, 2002

Chronic DPP-IV inhibition with FE-999011 delays development of diabetes

June 5, 2002

Xanthine oxidase inhibitors claimed by Teijin for use in gout, etc.

June 5, 2002

First orally active, selective MCH receptor antagonist identified at Takeda

June 4, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...